Erratum: (Arteriosclerosis, Thrombosis, and Vascular Biology (2015) 35 (221802224) DOI: 10.1161/ATVBAHA.115.305614);Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: Multicenter tracer kinetic study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 10, 2015, Pages 2218-2224

  Borén, Jan ^a   Watts, Gerald F ^b   Adiels, Martin ^a   Söderlund, Sanni ^d   Chan, Dick C ^b   Hakkarainen, Antti ^d   Lundbom, Nina ^d   Matikainen, Niina ^d   Kahri, Juhani ^d   Vergès, Bruno ^e   Barrett, P Hugh R ^b,c   Taskinen, Marja Riitta ^d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e INSERM   (France)

Author keywords

Apolipoproteins B; cardiovascular disease; Kinetics; Multicompartmental modeling; Obesity; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; STABLE ISOTOPE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN 1; LIPOPROTEIN; LIPOPROTEIN TRIGLYCERIDE; TRACER; VERY LOW DENSITY LIPOPROTEIN TRIGLYCERIDE;

ABDOMINAL OBESITY; ADULT; ARTICLE; CARDIOMETABOLIC RISK; CLINICAL ARTICLE; DISEASE ASSOCIATION; FAT CONTENT; FAT MASS; FEMALE; HIGH RISK PATIENT; HUMAN; INDEPENDENT VARIABLE; KINETIC PARAMETERS; LIPOLYSIS; LIVER SIZE; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SECRETION RATE; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; BIOLOGICAL MODEL; BLOOD; BODY MASS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DYSLIPIDEMIA; KINETICS; LIVER; METABOLISM; MULTICENTER STUDY; ORGAN SIZE; PATHOLOGY; REFERENCE VALUE; RISK ASSESSMENT;

ADIPOSE TISSUE; APOLIPOPROTEIN C-III; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; KINETICS; LIPOPROTEINS; LIPOPROTEINS, VLDL; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY, ABDOMINAL; ORGAN SIZE; RADIOACTIVE TRACERS; REFERENCE VALUES; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 84942246192     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATV.0000000000000026     Document Type: Erratum

References (55)

1. Joseph JJ, Golden SH. Type 2 diabetes and cardiovascular disease: what next? Curr Opin Endocrinol Diabetes Obes. 2014;21:109-120. doi: 10. 1097/MED. 0000000000000044.
2. Hiukka A, Fruchart-Najib J, Leinonen E, Hilden H, Fruchart JC, Taskinen MR. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia. 2005;48:1207-1215. doi: 10. 1007/s00125-005-1753-z.
3. Taskinen MR, Adiels M, Westerbacka J, Söderlund S, Kahri J, Lundbom N, Lundbom J, Hakkarainen A, Olofsson SO, Orho-Melander M, Borén J. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:2144-2150. doi: 10. 1161/ATVBAHA. 111. 224808.
4. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: A new paradigm. Endocr Rev. 2015;36:131-147. doi: 10. 1210/er. 2014-1062.
5. Adiels M, Westerbacka J, Soro-Paavonen A, Häkkinen AM, Vehkavaara S, Caslake MJ, Packard C, Olofsson SO, Yki-Järvinen H, Taskinen MR, Borén J. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia. 2007;50:2356-2365. doi: 10. 1007/s00125-007-0790-1.
6. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Häkkinen A, Olofsson SO, Yki-Järvinen H, Borén J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765. doi: 10. 1007/ s00125-005-0125-z.
7. Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta. 2014;1841:919-933. doi: 10. 1016/j. bbalip. 2014. 03. 013.
8. Goulbourne CN, Gin P, Tatar A, et al. The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metab. 2014;19:849-860. doi: 10. 1016/j. cmet. 2014. 01. 017.
9. Williams KJ. Molecular processes that handle-and mishandle-dietary lipids. J Clin Invest. 2008;118:3247-3259. doi: 10. 1172/JCI35206.
10. Ooi EM, Russell BS, Olson E, Sun SZ, Diffenderfer MR, Lichtenstein AH, Keilson L, Barrett PH, Schaefer EJ, Sprecher DL. Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations. Arterioscler Thromb Vasc Biol. 2012;32:459-466. doi: 10. 1161/ATVBAHA. 111. 238493.
11. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297:E271-E288. doi: 10. 1152/ ajpendo. 90920. 2008.
12. Chatterjee C, Sparks DL. Hepatic lipase, high density lipoproteins, and hypertriglyceridemia. Am J Pathol. 2011;178:1429-1433. doi: 10. 1016/j. Ajpath. 2010. 12. 050.
13. Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem. 2011;48(Pt 6):498-515. doi: 10. 1258/acb. 2011. 011111.
14. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res. 2002;43:1997-2006.
15. Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol. 2010;21:409-415. doi: 10. 1097/MOL. 0b013e32833ded83.
16. Lafferty MJ, Bradford KC, Erie DA, Neher SB. Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation. J Biol Chem. 2013;288:28524-28534. doi: 10. 1074/jbc. M113. 497602.
17. Dijk W, Kersten S. Regulation of lipoprotein lipase by Angptl4. Trends Endocrinol Metab. 2014;25:146-155. doi: 10. 1016/j. Tem. 2013. 12. 005.
18. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism. 2012;61:906-921. doi: 10. 1016/j. metabol. 2011. 12. 002.
19. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287-1295. doi: 10. 1172/ JCI112713.
20. Larsson M, VorrsjÖ E, Talmud P, Lookene A, Olivecrona G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 2013;288:33997-34008. doi: 10. 1074/jbc. M113. 495366.
21. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26:556-565.
22. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceriderich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266:18259-18267.
23. Inazu A, Nakajima K, Nakano T, Niimi M, Kawashiri MA, Nohara A, Kobayashi J, Mabuchi H. Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. Atherosclerosis. 2008;196:953-957. doi: 10. 1016/j. Atherosclerosis. 2007. 02. 028.
24. Diffenderfer MR, Brousseau ME, Millar JS, Barrett PH, Nartsupha C, Schaefer PM, Wolfe ML, Dolnikowski GG, Rader DJ, Schaefer EJ. Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism. J Lipid Res. 2012;53:1190-1199. doi: 10. 1194/ jlr. M019570.
25. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972;46:375-382.
26. Havel RJ, Fielding CJ, Olivecrona T, Shore VG, Fielding PE, Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry. 1973;12:1828-1833.
27. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj. rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32-41. doi: 10. 1056/NEJMoa1308027.
28. TG, HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in apoc3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22-31
29. Ginsberg HN, Brown WV. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol. 2011;31:471-473. doi: 10. 1161/ATVBAHA. 110. 221846.
30. Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burkey J, Crooke ST, Crooke RM. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479-1490. doi: 10. 1161/CIRCRESAHA. 111. 300367.
31. Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, De Roy L. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 1989;77:139-149.
32. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005;115:1323-1332. doi: 10. 1172/JCI23219.
33. Chan DC, Nguyen MN, Watts GF, Ooi EM, Barrett PH. Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clin Nutr. 2010;91:900-906. doi: 10. 3945/ajcn. 2009. 28422.
34. Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26:56-63. doi: 10. 1097/MOL. 0000000000000146.
35. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200-2206. doi: 10. 1056/NEJMoa1400284.
36. Huard K, Bourgeois P, Rhainds D, Falstrault L, Cohn JS, Brissette L. Apolipoproteins C-II and C-III inhibit selective uptake of low-and highdensity lipoprotein cholesteryl esters in HepG2 cells. Int J Biochem Cell Biol. 2005;37:1308-1318. doi: 10. 1016/j. biocel. 2005. 01. 005.
37. Sacks FM, Zheng C, Cohn JS. Complexities of plasma apolipoprotein C-III metabolism. J Lipid Res. 2011;52:1067-1070. doi: 10. 1194/jlr. E015701.
38. Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res. 2007;48:1190-1203. doi: 10. 1194/ jlr. P600011-JLR200.
39. Le NA, Gibson JC, Ginsberg HN. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 1988;29:669-677.
40. Breslow JL, Zannis VI, SanGiacomo TR, Third JL, Tracy T, Glueck CJ. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res. 1982;23:1224-1235.
41. Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of verylow-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol. 2010;30:239-245. doi: 10. 1161/ATVBAHA. 109. 197830.
42. Chan DC, Watts GF, Nguyen MN, Barrett PH. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol. 2006;26:590-596. doi: 10. 1161/01. ATV. 0000203519. 25116. 54.
43. Korn ED. Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem. 1955;215:1-14.
44. Huttunen JK, Ehnholm C, Kekki M, Nikkilä EA. Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridaemia: correlations to sex, age and various parameters of triglyceride metabolism. Clin Sci Mol Med. 1976;50:249-260.
45. Pruneta V, Autran D, Ponsin G, Marcais C, Duvillard L, Verges B, Berthezene F, Moulin P. Ex vivo measurement of lipoprotein lipasedependent very low density lipoprotein (VLDL)-triglyceride hydrolysis in human VLDL: An alternative to the postheparin assay of lipoprotein lipase activity? J Clin Endocrinol Metab. 2001;86:797-803. doi: 10. 1210/ jcem. 86. 2. 7261.
46. Goldberg IJ, Kandel JJ, Blum CB, Ginsberg HN. Association of plasma lipoproteins with postheparin lipase activities. J Clin Invest. 1986;78:1523-1528. doi: 10. 1172/JCI112744.
47. Vilella E, Joven J, Fernández M, Vilaró S, Brunzell JD, Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res. 1993;34:1555-1564.
48. Carrero P, Gómez-Coronado D, Olivecrona G, Lasunción MA. Binding of lipoprotein lipase to apolipoprotein B-containing lipoproteins. Biochim Biophys Acta. 1996;1299:198-206.
49. Zambon A, Schmidt I, Beisiegel U, Brunzell JD. Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins. J Lipid Res. 1996;37:2394-2404.
50. Zheng C, Murdoch SJ, Brunzell JD, Sacks FM. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler Thromb Vasc Biol. 2006;26:891-896. doi: 10. 1161/01. ATV. 0000203512. 01007. 3d.
51. Chevreuil O, Hultin M, Ostergaard P, Olivecrona T. Heparindecasaccharides impair the catabolism of chylomicrons. Biochem J. 1996;320 (Pt 2):437-444.
52. Chan DC, Watts GF, Ooi EM, Chan DT, Wong AT, Barrett PH. Apolipoprotein A-II and adiponectin as determinants of very lowdensity lipoprotein apolipoprotein B-100 metabolism in nonobese men. Metabolism. 2011;60:1482-1487. doi: 10. 1016/j. metabol. 2011. 03. 003.
53. Magkos F, Fabbrini E, Patterson BW, Eagon JC, Klein S. Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects. Metabolism. 2011;60:1641-1648. doi: 10. 1016/j. metabol. 2011. 03. 019.
54. Lapointe A, Tchernof A, Lamarche B, Piché ME, Weisnagel J, Bergeron J, Lemieux S. Plasma adiponectin concentration is strongly associated with VLDL-TG catabolism in postmenopausal women. Nutr Metab Cardiovasc Dis. 2011;21:254-260. doi: 10. 1016/j. numecd. 2009. 10. 007.
55. Ramakrishnan S, Ginsberg H. Modeling the VLDL delipidation cascade: Apolipoprotein B and triglyceride pools have identical rate constants despite different fates and mass distributions [abstract]. 17th International Atherosclerosis Society Congress, Amsterdam; 2015. http://www. isa-2015. com/program/scientific-programme/.